Kaff2 Citrate
Also known as: Caffeine citrate, caffeine salt of citric acid, Kaff2 Citrate
Overview
Caffeine citrate is a citrate salt form of caffeine, primarily utilized as a pharmaceutical agent rather than a dietary supplement. It is synthesized for medical applications, most notably in neonatal care. Its main use is in the treatment of apnea of prematurity, a condition characterized by intermittent cessation of breathing in preterm infants, where it is administered intravenously or orally in neonatal intensive care units. Key characteristics include a rapid onset of action, a longer half-life compared to caffeine base, and improved solubility and bioavailability. Extensive clinical research, including numerous systematic reviews and meta-analyses, particularly within neonatal medicine, supports its efficacy and safety profile. The quality of evidence is high, derived from randomized controlled trials (RCTs) and meta-analyses, confirming its role as a standard treatment.
Benefits
Caffeine citrate offers significant, evidence-based benefits primarily for preterm infants. It is highly effective in reducing episodes of apnea in preterm infants, demonstrating similar efficacy to aminophylline but with fewer side effects, particularly a lower incidence of tachycardia (OR 0.22, 95% CI 0.13–0.37, p<0.001). Early administration of caffeine therapy is associated with a notable 20% reduction in the incidence of bronchopulmonary dysplasia (BPD) in preterm neonates. Furthermore, it has been linked to reduced mortality and improved neurodevelopmental outcomes in this vulnerable population. These benefits are observed within 1-3 days of treatment initiation for apnea, with longer-term respiratory and neurodevelopmental advantages seen with early intervention. The evidence supporting these benefits is robust, stemming from high-quality systematic reviews and meta-analyses of randomized controlled trials.
How it works
Caffeine citrate functions primarily as a non-selective adenosine receptor antagonist, blocking A1 and A2A receptors. This action leads to stimulation of the central nervous system and respiratory centers, enhancing respiratory drive and increasing diaphragmatic contractility. It improves lung function and has mild diuretic and cardiac stimulant effects. Its molecular targets are adenosine receptors located in the brainstem respiratory centers. The citrate salt form significantly improves its solubility and absorption compared to caffeine base, contributing to its high bioavailability and rapid onset of action.
Side effects
Caffeine citrate is generally well-tolerated in neonatal populations and exhibits a more favorable side effect profile compared to aminophylline. Common side effects (occurring in >5% of patients) include tachycardia (though less frequent than with aminophylline), feeding intolerance, and jitteriness. Uncommon side effects (1-5%) may involve gastrointestinal disturbances and mild irritability. Rare side effects (<1%) can include seizures, typically in cases of overdose, and arrhythmias. Caffeine metabolism can be influenced by drugs that alter CYP1A2 enzyme activity, necessitating caution with co-administration. Contraindications include hypersensitivity to caffeine or citrate. It should be used with caution in infants with pre-existing cardiac arrhythmias. While primarily studied and used in preterm infants, its use in adults is outside its typical indication, and safety data for other populations are limited.
Dosage
For preterm infants, the minimum effective dose typically involves a loading dose of approximately 20 mg/kg caffeine citrate, followed by maintenance doses ranging from 5-10 mg/kg/day (caffeine citrate equivalent). Optimal dosage ranges for maintenance are generally up to 10 mg/kg/day, with higher doses increasing the risk of adverse effects. The maximum safe dose in clinical trials has been up to 20 mg/kg/day for maintenance, but doses exceeding this significantly elevate the risk of adverse events. Early initiation of treatment, ideally within the first two days of life, is strongly recommended as it is associated with better respiratory and neurodevelopmental outcomes. Caffeine citrate is administered in intravenous or oral formulations, with the citrate salt form specifically chosen for its enhanced solubility and absorption. No specific cofactors are required for its efficacy.
FAQs
Is caffeine citrate safe for preterm infants?
Yes, caffeine citrate is considered safe and is the standard treatment for apnea of prematurity, with a favorable safety profile compared to alternative treatments like aminophylline.
When should caffeine citrate be started?
Early initiation, ideally within the first two days of life, is recommended for optimal respiratory and neurodevelopmental outcomes in preterm infants.
How long does it take to see effects?
Respiratory improvements, such as a reduction in apnea episodes, are typically observed within 1-3 days of initiating caffeine citrate treatment.
Can caffeine citrate cause heart problems?
Tachycardia (increased heart rate) can occur, but it is less frequent and generally less severe than with other similar medications. Monitoring is advised during treatment.
Is caffeine citrate the same as caffeine?
Caffeine citrate is a specific salt form of caffeine, designed for medical use. It has improved solubility and absorption properties compared to pure caffeine, making it suitable for pharmaceutical applications.
Research Sources
- https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0274882 – This systematic review and meta-analysis compared caffeine citrate and aminophylline for apnea of prematurity. It found that both drugs have similar efficacy in reducing apnea episodes, but caffeine citrate is associated with significantly fewer side effects, particularly tachycardia, making it a safer option for preterm infants.
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5338164/ – This systematic review and meta-analysis of cohort studies investigated the impact of early versus late caffeine therapy in preterm infants. It concluded that early administration of caffeine significantly reduces the incidence of bronchopulmonary dysplasia (BPD) by approximately 20% and improves mortality outcomes, highlighting the importance of timely intervention.
- https://pubmed.ncbi.nlm.nih.gov/38553606/ – This systematic review and meta-analysis, encompassing 15 randomized controlled trials, explored the dose-effect relationship and overall efficacy and safety of caffeine in preterm infants. It affirmed that caffeine is an effective and safe treatment for apnea of prematurity, with early treatment providing significant benefits for long-term outcomes.
Supplements Containing Kaff2 Citrate
Recommended Articles
Top Ingredients for Healthy Blood Pressure
Dietary ingredients like potassium, magnesium, and the DASH diet play crucial roles in managing blood pressure.
Absorption-Optimized Multivitamins: Key Ingredients
Bioavailable forms of vitamins and chelated minerals in multivitamins ensure better absorption and effectiveness.
Magnesium Dosage Guide: Safe & Effective Use
Magnesium's optimal dosage varies by form and individual needs, with an RDA of 310-420 mg/day for adults.
Top Zinc Forms for Best Absorption & Dosage Guide
Zinc picolinate is the most absorbable form of zinc, with an RDA of 8-11 mg/day for adults, affected by dietary factors.